Italian pharmaceutical group Mediolanum Farmaceutici and its CEO Alessandro Del Bono have renewed their partnership with Ardian as they seek to continue the company’s impressive growth after four years of strong performance. This includes establishing further ambitious development projects for Neopharmed Gentili and welcoming Neuberger Berman as a new shareholder in the Group.
Under the agreement, Mediolanum Farmaceutici will maintain a significant stake in Neopharmed Gentili and Alessandro Del Bono will continue to lead the company as CEO and Chairman of the Board of Directors.
Headquartered in Milan, Neopharmed Gentili is one of the main pharmaceutical companies operating in the Italian market. With of one of the largest networks of pharma representatives in Italy, Neopharmed Gentili is a market leader in therapeutic areas such as cardiovascular and neurology.
In partnership with Ardian, Neopharmed Gentili pursued a long-term growth strategy, expanding both organically and through an ambitious buy-and-build plan, which resulted in six M&A transactions in four years. This growth plan also saw the Company strengthen and diversify its product portfolio, achieving revenues of €250m.
Through the renewed agreement, the Del Bono family, Ardian and NB Renaissance have laid the foundations to continue to drive growth, supporting the company and its management team by providing new capital.
“We are very excited about the future. The partnership with Ardian and NB Renaissance represents an important step forward in the history of Neopharmed Gentili, which will assure to be increasingly competitive in a context of growing complexity and will open new markets. We have achieved the goal of making Neopharmed Gentili a solid and credible player in the Italian pharmaceutical market thanks to the high scientific value of our solutions and the widely recognized quality of our team of professionals. Today we have new challenges and new goals, and we look forward to being able to continue to grow and create value, always preserving our culture and identity.” Alessandro Del Bono, CEO and Chairman - Neopharmed Gentili
"We are extremely proud of the relationship established with Alessandro Del Bono and with the entire management team of Neopharmed Gentili. As a result of our partnership, the company has achieved brilliant results over the past four years, and we are convinced there are numerous continued growth opportunities in Italy and abroad. We believe that this partnership with NB Renaissance will facilitate further consolidation and international development, while safeguarding the current corporate culture.” Nicolò Saidelli, Member of the Executive Committee, Head of Ardian Italy and Deputy Head of Buyout - Ardian
"We are very grateful that the Del Bono family and Ardian have chosen NB Renaissance as a new partner and we strongly feel the responsibility to support Neopharmed’s growth, development and value creation. Based on our long-standing expertise in the pharma industry, we believe we can make a significant contribution to the success of the company and its stakeholders.” Fabio Canè, Co-Founder and Senior Partner - NB Renaissance
Ardian is a world leading private investment house, managing or advising $141bn of assets on behalf of more than 1,300 clients globally. Our broad expertise, spanning Private Equity, Real Assets and Credit, enables us to offer a wide range of investment opportunities and respond flexibility to our clients’ differing needs. Through Ardian Customized Solutions we create bespoke portfolios that allow institutional clients to specify the precise mix of assets they require and to gain access to funds managed by leading third-party sponsors. We also provide a specialist service for private clients through Ardian Private Wealth Solutions. Ardian is majority-owned by its employees and places great emphasis on developing its people and fostering a collaborative culture based on collective intelligence. Our 990+ employees, spread across 15 offices in Europe, the Americas and Asia, are strongly committed to principles of Responsible Investment and are determined to make finance a force for good in society. Our goal is to deliver excellent investment performance combined with high ethical standards and social responsibility. At Ardian we invest all of ourselves in building companies that last.
Initially established within the Mediolanum Farmaceutici Group, which was founded in 1972 by the Del Bono family, Neopharmed Gentili is a company specialised in the commercialisation of pharmaceutical products in the Italian market. Headquartered in Milan and led by Alessandro Del Bono, it is one of the main pharmaceutical companies in the Italian market, especially in the cardiovascular and neurological therapeutic areas. Over the years, Neopharmed Gentili’s development was also supported by external growth through partnerships and acquisitions.
NB Renaissance is an investment firm with a focus on international companies based in Italy that trade in resilient sectors with high growth potential. NB Renaissance currently manages over €2.3 billion in assets and is invested in 13 companies with an aggregate turnover of approximately €6 billion and 20,000 employees.
The strategy is diversified into four main investment themes: digital, sustainability, healthcare and specialized industrials, with high added value intermediate products. Growth initiatives are at the heart of the value creation model. NB Renaissance supports entrepreneurs and managers in their companies' growth plans with a partnership approach.